Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.

Moore, Jeremiah; Baran, Andrea M; Meacham, Philip J; Evans, Andrew G; Barr, Paul M; Zent, Clive S

Moore, Jeremiah; Baran, Andrea M; Meacham, Philip J; Evans, Andrew G; Barr, Paul M; Zent, Clive S.

Afiliação

Moore J; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Baran AM; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Meacham PJ; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Evans AG; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Barr PM; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Zent CS; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.

Am J Hematol ; 95(5): E108-E110, 2020 05.

Article em En | MEDLINE | ID: mdl-31951033

Assuntos

Leucemia Prolinfocítica Tipo Células B/tratamento farmacológico; Pirazóis/uso terapêutico; Pirimidinas/uso terapêutico; Adenina/análogos & derivados; Idoso; Feminino; Humanos; Leucemia Prolinfocítica Tipo Células B/mortalidade; Masculino; Piperidinas; Análise de Sobrevida

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Prolinfocítica Tipo Células B Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google